FDA expands Vertex Casgevy label to patients aged 2 and older, making about 5,500 more U.S. children

- First and only approved genetic therapy to treat children as young as 2 years for both severe sick

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the

The U.S. Food and Drug Administration approved expanded use of Vertex Pharmaceuticals' gene therapy

https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-young-children-s

Dyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its prop

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the

Vertex Pharmaceuticals Incorporated maintains a dominant, monopoly position in cystic fibrosis, driv

Jim Lebenthal recommends Vertex Pharmaceuticals in the healthcare sector. Jenny Van Leeuwen picks Ve

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 8.53% on a

CRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $491.34, denoting a

Vertex Reports CASGEVY Data Showing Sustained Benefits In Children With Sickle Cell Disease And Beta

- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or tran

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administra

– Suzetrigine, a selective pain signal inhibitor, has the potential to treat millions of Canadians w

Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight an

Canaccord Genuity analyst Whitney Ijem maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold

Vertex Pharmaceuticals Inc reported mixed financial results for Q1, with revenue of $2.99B and adju

Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overwe

Bernstein analyst William Pickering maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperf

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperfo

Vertex Pharma posts revenue beat but misses EPS expectations. CF franchise remains strong, says Need

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports financial results for the first quarter after the m

Vertex Pharmaceuticals (NASDAQ:VRTX) affirms FY2026 sales outlook from $12.950 billion-$13.100 billi

Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.47 per share which beat the a

U.S. stocks sank Monday as an Iranian drone attack on a UAE petroleum site sent Brent above $114, go

The Fear & Greed Index measures market sentiment based on fear and greed levels, showing little

Focus on earnings reports from Tyson Foods, Williams Companies, Skycorp Solar, Vertex Pharmaceutical

Canaccord Genuity analyst Whitney Ijem maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold

Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overwe

U.S. stocks rose broadly on Tuesday as crude oil plunges over 10% on Trump's Iran end-of-war sig

CRISPR Therapeutics fell Tuesday after unveiling a $350 million convertible notes offering, overshad

Dow Jones index up 200 points on Tuesday, NIO Inc. gained following better-than-expected financial r

Vertex's kidney drug delivers a "clear win" in Phase 3. Clinical success and a 6% premar

After Thursday's broad-based tech selloff, Wall Street staged a rebound as a softer-than-expecte

CRISPR Therapeutics highlights progress in clinical trials & uptake of Casgevy gene therapy. Pip

Investors are anticipating reports from Robinhood, Pinterest, Rivian and more. Here's a look at

Kimberly Clark, S&P Global Inc, Vertex Pharmaceuticals and Exxon Mobil each get shoutouts on CNB

Vertex Pharmaceuticals shares dipped slightly in after-hours trading following Wednesday's sessi

Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as s